Enlivex (ENLV) has released an update.
Enlivex Therapeutics Ltd. is inviting investors to an informative webinar on June 25, 2024, featuring updates on the company’s breakthrough immunotherapy product, Allocetra™, and insights from their CEO, Dr. Oren Hershkovitz. The webinar will highlight promising Phase I/II trial results for Allocetra™, showing significant pain reduction in severe knee osteoarthritis patients, and will also cover the company’s clinical program progress and financial status after a recent funding round.
For further insights into ENLV stock, check out TipRanks’ Stock Analysis page.
